, Volume 22, Issue 2, pp 73–77 | Cite as

Efficacy of some colloidal silver preparations and silver salts against Proteus bacteria, one possible cause of rheumatoid arthritis

  • D. M. B. T. Disaanayake
  • Joan Faoagali
  • Hans Laroo
  • Gerald Hancock
  • Michael Whitehouse
Short Communication


There has been increased interest in the role of anti-Proteus antibodies in the aetiology of rheumatoid arthritis (RA) and whether chemotherapeutic agents active against Proteus species might reduce the risk and/or exacerbations of RA. We examined the in vitro antibacterial effects of ten different silver preparations which were either ionic silver [Ag(I)] solutions or nanoparticulate silver (NPS) (Ag0) suspensions against ATCC and two wild (clinical) strains of Proteus. The data establish the low minimum inhibitory concentration and minimum bactericidal concentration of all the silver formulations tested against these four Proteus strains. In a pilot study, a potent NPS preparation ex vivo showed long-lasting anti-Proteus activity in a normal human volunteer.


Proteus Rheumatoid arthritis Silver antimicrobials Nanoparticulate silver 



We are indebted to A White and J Petty for advice and assistance with silver analyses; to M Baharevs (Sydney) and Academician V Nesterov (Omsk) for assistance and advice in using the MetAtron monitor; to Dr G Maas (USA) for providing Meso Silver; and to D Butters for preparing the final MS. The Brisbane Holland Park Lions Club and W Whitney (and friends) helped fund the NPS studies.


  1. Chandler RW, Robinson H, Masi AT (1971) Serological investigations for evidence of an infectious aetiology of rheumatoid arthritis. Ann Rheum Dis 30:274–278PubMedCentralPubMedCrossRefGoogle Scholar
  2. Cock I, van Vuuren SF (2013) Anti-Proteus activity of some South African medicinal plants: their potential for the prevention of rheumatoid arthritis. Inflammopharmacology. doi: 10.1007/s10787-013-0179-3 PubMedGoogle Scholar
  3. Cock I, Mohanty S, White A, Whitehouse M (2012) Colloidal silver (CS) as an antiseptic: two opposing viewpoints. Pharmacog Comm 2:47–56CrossRefGoogle Scholar
  4. Dayanand S, Dayanand A, Sreedhar B, Dastager SG (2010) Antimicrobial activity of silver nanoparticles synthesized from novel Streptomyces species. Dig J Nanomater Bios 5:447–451Google Scholar
  5. Deighton CM, Gray J, Bint AJ, Walker DJ (1992a) Anti-Proteus antibodies in rheumatoid arthritis same-sexed sibships. Br J Rheumatol 31:241–245PubMedCrossRefGoogle Scholar
  6. Deighton CM, Gray SW, Bint AJ, Walker DJ (1992b) Specificity of the Proteus antibody response in rheumatoid arthritis. Ann Rheum Dis 51:1206–1207PubMedCentralPubMedCrossRefGoogle Scholar
  7. Ebringer A (2012) Rheumatoid arthritis and Proteus. Springer, London, p 223Google Scholar
  8. Ebringer A, Rashid T, Wilson C (2003) Rheumatoid arthritis: proposal for the use of antimicrobial therapy in early cases. Scand J Rheumatol 32:2–11PubMedCrossRefGoogle Scholar
  9. Eckhardt S, Brunetto PS, Gagnon J, Prieve M, Geise B, Fromm KM (2013) Nanobio Silver: its interactions with peptides and bacteria, and its uses in medicine. Chem Rev 113:4708–4754PubMedCrossRefGoogle Scholar
  10. Fairley KF, Carson NE, Gutch RC, Leighton PO, Grounds AD, Laird EC et al (1971) Site of infection in acute urinary tract infection in general practice. Lancet 2:615PubMedCrossRefGoogle Scholar
  11. Ferrara P, Romaniello L, Vitelli O, Gatto A, Serva M, Cataldi L (2009) Cranberry juice for the prevention of recurrent urinary tract infections: a randomized controlled trial in children. Scand J Urol Nephrol 43:369–372PubMedCrossRefGoogle Scholar
  12. Kim JS, Kuk E, Yu KN, Kim J, Park SJ, Lee HJ et al (2007) Antimicrobial effects of silver nanoparticles. Nanomedicine 3:95–101PubMedCrossRefGoogle Scholar
  13. Laroo H (2013) Colloidal nanosilver—its production method, properties, standards, and its bio-efficacy as an inorganic antibiotic. J Phys Chem Biophys ( ISSN: 2161-0398)Google Scholar
  14. Lee H, Ko KS, Song JH, Peck KR (2011) Antimicrobial activity of doripenem and other carbapenems against gram-negative pathogens from Korea. Microb Drug Resist 17:37–45PubMedCrossRefGoogle Scholar
  15. Liu J, Sonshine DA, Shervani S, Hurt RH (2010) Controlled release of biologically active silver from nanosilver surfaces. NANO 4:6903–6913Google Scholar
  16. Lo B (2010) Ethical issues in clinical research: a practical guide. Walters Kluwer, Philadelphia, p 292Google Scholar
  17. Marambio-Jones C, Hoek EMV (2010) A review of the antibacterial effects of silver nanomaterials and potential implications for human health and the environment. J Nanopart Res 12:1531–1551CrossRefGoogle Scholar
  18. O’Hara CM, Brenner FW, Miller JM (2000) Classification, identification and clinical significance of Proteus, Providencia and Morganella. Clin Microbiol Rev 13:534–546PubMedCentralPubMedCrossRefGoogle Scholar
  19. Rashid T, Ebringer A (2007) Rheumatoid arthritis is linked to Proteus—the evidence. Clin Rheumatol 26:1036–1043PubMedCrossRefGoogle Scholar
  20. Rashid T, Ebringer A (2011) Rheumatoid arthritis is caused by asymptomatic Proteus urinary tract infections. In: Nikibakhsh A (ed) Clinical management of complicated urinary tract infection. In-Tech. vol 11Google Scholar
  21. Rashid T, Tiwana H, Wilson C, Ebringer A (2001) Rheumatoid arthritis as an autoimmune disease caused by Proteus urinary tract infections: a proposal for a therapeutic protocol. Israeli Med Assoc J (IMAJ) 3:675–680Google Scholar
  22. Senior BW, Anderson GA, Morley KD, Ma Kerr (1999) Evidence that patients with rheumatoid arthritis have asymptomatic ‘non-significant’ Proteus mirabilis bacteriuria more frequently than healthy controls. J Infect 8:99–106CrossRefGoogle Scholar
  23. Sylver N (2009) Handbook of frequency therapy. Desert Gate, Phoenix, p 732Google Scholar
  24. Tiwana H, Wilson C, Cunningham P, Binder A, Ebringer A (1996) Antibodies to four gram-negative bacteria in rheumatoid arthritis which share sequences with the rheumatoid arthritis susceptibility motif. Br J Rheum 35:592–594CrossRefGoogle Scholar
  25. Varner K, El-Badaway A, Feldhake D, Venkatapathy R (2010) State of the science literature review: everything nanosilver and more. US Environmental Protection Agency, Washington DC, p 363Google Scholar
  26. Whitehouse M, Butters D, Vernon-Roberts B (2013) Conditional pharmacology/toxicology V: ambivalent effects of thiocyanate upon the development and the inhibition of experimental arthritis in rats by aurothiomalate (MyocrysinR) and metallic silver. Inflammopharmacology 21:291–300PubMedCrossRefGoogle Scholar
  27. Wilson C, Thakore D, Isenberg D, Ebringber A (1997) Correlation between anti-Proteus antibodies and isolation rates of P. mirabilis in rheumatoid arthritis. Rheumatol Int 16:187–189PubMedCrossRefGoogle Scholar
  28. Xiu Z-M, Zhang Q-B, Puppala HL, Colvin VL, Alvarez PJJ (2012) Negligible particle-specific antibacterial activity of silver nanoparticles. Nano Lett 12:4271–4275PubMedCrossRefGoogle Scholar

Copyright information

© Springer Basel 2014

Authors and Affiliations

  • D. M. B. T. Disaanayake
    • 1
    • 5
  • Joan Faoagali
    • 1
  • Hans Laroo
    • 2
  • Gerald Hancock
    • 3
  • Michael Whitehouse
    • 4
  1. 1.Pathology QueenslandPrincess Alexandra HospitalBrisbaneAustralia
  2. 2.Laroo ResearchIpswichAustralia
  3. 3.Wellness Focus Centre (WFC)BrisbaneAustralia
  4. 4.School of Biomolecular and Physical SciencesGriffith UniversityBrisbaneAustralia
  5. 5.Microbiology DepartmentUniversity of Sri JayewardenepuraSri Jayewardenepura KotteSri Lanka

Personalised recommendations